Posted by Michael Wonder on 02 Apr 2019
NICE nod for breast cancer delay drug
2 April 2019 - NICE has recommended Eli Lilly’s Verzenio (abemaciclib) when given with Faslodex (fulvestrant), to be available for NHS use within the Cancer Drugs Fund.
The decision is based on clinical trial evidence suggesting that compared with Faslodex alone, Verzenio with Faslodex increases the length of time before the disease progresses.
However, there is a lack of evidence around the overall survival benefit and around its cost-effectiveness, meaning it has been recommended for use within the Cancer Drugs Fund while more data is collected.
